Physician profile
Neil Soskel
NPI 1417942210
$27,760.28
in general payments reported to CMS, 2019-2025
62 companies · $3,013 in 2025
The $3,013 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,444 · 2020: $4,922 · 2021: $5,238 · 2022: $3,127 · 2023: $2,923 · 2024: $3,094 · 2025: $3,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,989 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,988.74 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,142.12 | 2019-2025 | |
| Novo Nordisk INC | $3,239.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,052.45 | 2019-2025 | Farxiga, Airsupra, Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,800.38 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,773.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,432.78 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,401.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Mannkind Corporation | $1,247.59 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,238.40 | 2021 | |
| Amgen INC. | $1,195.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $834.59 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $601.47 | 2021-2025 | |
| Amarin Pharma, INC. | $595.59 | 2019-2021 | |
| Allergan, INC. | $546.00 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $450.30 | 2019-2023 | Livalo, Seglentis |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Soskel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.